Microsoft word - cv dr banu english 03.02.2011.doc

Eugeniu BANU, MD.

BOARD CERTIFICATIONS
2010
Inscription to the UK General Medical Council (ongoing application) Inscription to the French Medical Council, city of Paris (license 75.73889, RPPS number: 10004405956) Inscription to the Romanian Medical Council (license CJ-1228) Authorization procedure of the medical profession in France Board Certified Medical Oncologist (license 1578) Doctor of Medicine, graduated Cum Laude
EDUCATION AND TRAINING
1993 – 1998
Residency in Medical Oncology, Cluj-Napoca, Romania Postgraduate internship (internal medicine, gynecology, pediatry, surgery) School of Medicine, University of Cluj, Romania PROFESSIONAL QUALIFICATIONS (FRANCE) June 09 – Aug 09 Bayer Santé, Bayer Schering Pharma, Lille Clinical Research Physician, Medical Affairs Division Georges Pompidou European Hospital, Paris Medical Oncology Department: Senior Oncologist, Senior Clinical Research Scientist, Head of Clinical Research and Biostatistics Unit Gustave Roussy Cancer Center, Villejuif Medical Oncology Department: Associate Medical Doctor Alexis Vautrin Cancer Center, Nancy Medical Oncology Department: Associate Medical Doctor Jun 97 – Sep 97 Henri Becquerel Cancer Center, Rouen Medical Oncology Department: Clinical Fellow PROFESSIONAL QUALIFICATIONS (ROMANIA) Jan 11 – today Saint Constantin Private Hospital, Brasov Medical Director, Head of Medical Oncology Department Cancer Institute, Medical Oncology Department, Cluj-Napoca Cancer Institute, Medical Oncology Department, Cluj-Napoca University of Medicine, Cluj-Napoca Fel ow in Biostatistics and Bioinformatics • Full member of the European Society for Medical Oncology (ESMO) • Member of the European Association for Cancer Research (EACR) • Member of the International Gynecologic Cancer Society (IGCS) • Affiliate member of the European Association of Urology (EAU) • Active member of the European Society of Gynaecological Oncology (ESGO) • Member of the International Association for the Study of Lung Cancer (IASLC) • Member of the Society for Translational Oncology (STO) • Member of the International Society of Gastrointestinal Oncology (ISGO) • Member of the European Society of Breast Cancer Specialists (EUSOMA) • Member of the European Society of Digestive Oncology (ESDO) • Regular member of the American Statistical Association (ASA) • Fel ow member of the Royal Statistical Society (RSS) • Member of the International Society for Clinical Biostatistics (ISCB) • Member of the World Oncology Network (WON) • Member of the National Cervical (NCCC) and Prostate Cancer (NPCC) Coalition • Member of IRMA (Renal Insufficiency and Cancer Medications) Study Group • Investigator in phase I to IV international and national clinical trials in oncology • Clinical trial leader for studies promoted by the research unit • Coordinated a clinical research unit in oncology (two project managers, one clinical research physician, three clinical research associates, one clinical research technician) • Coordinated the activity between the Clinical Research Unit in Oncology and Biology, Pathology, Radiology, Immunology and Laboratory Departments • Ability to coordinate al aspects of study management: develop and implement study design, data management, contribute to regulatory submission, analyze and interpret data, prepare written plans and reports for statistical design and data analysis • Provide biostatistical expertise, instructions for planning and performing clinical studies and reporting procedures according to the SOPs (ICH and WHO GCP standards) • Statistical analysis (SPSS, EpiInfo), including meta-analysis software support (EasyMA and Review Manager Cochrane Col aboration's) • Consultant and fully trained in relational database management systems (RDBMSs) design as administrator (FileMaker Pro and FileMaker Server) • Design, management and support for the electronic Case Record Form, using RDBMSs technology, streamlined Data Collection and Query Resolution, Electronic Data Capture • Implement and maintain computerized information systems (network administrator) • Designed and implemented a computerized chemotherapy prescription system available on the Internet and Intranet, compliant with GCP requirements • Advanced user for Microsoft Office package including Access • Bibliographic software support for peer-review publication (Endnote X) • Statistical methods for biomedical applications: o survival analysis, adaptative design, group-sequential methods o randomization (minimisation, stratification, blocking) with software support o statistical aspects of study design, sample size estimation, data analysis, statistical tables, graphs and listings, statistical reporting and report writing • Medical Reviewer for 10 peer-review journals in oncology (58 reviewed articles): o Journal of Clinical Oncology (since April 2006), Annals of Oncology (May 2007), Contemporary Clinical Trials (November 2007), Cancer (May 2008), American Journal of Clinical Oncology (June 2008), Gynecologic Oncology and International Journal of Clinical Practice (August 2008), Journal of Experimental & Clinical Cancer Research (March 2010), Journal of Men’s Health (July 2010), The Open Lung Cancer Journal (November 2010) • Lead Guest Editor for one of upcoming Special Issues for Prostate Cancer Journal • Active member (consulting services): o Gerson Lehrman Group Healthcare Councils o Medefield® Healthcare Advisory Board
o Omnimed Santé Kantar Health Panel®
o Guidepoint Global Advisors®
o 2009 Edition of Who's Who in the World® (Marquis Publisher, USA)
o 2009-2010 Edition of Who's Who in Medicine and Healthcare® (Marquis)
o 2000 Outstanding Intel ectuals of the 21st Century Awards (International o 100 Health Professionals 2009 (International Biographical Centre) • Nominated for 2010-2011 Edition, Who's Who in Science and Engineering® (Marquis)
• Author of the statistical analysis of peer-review articles published in Cancer (ref 11), J Clin
Oncol (22-23), Ann Oncol (15), J Neuro Oncol (24), J Urol (ref 19), Prostate (16), Drugs & Aging (14), Eur Urol (4, 9), BJU Int (3), Radiology (2), oral presentations (1-4, 7-9), posters (1-3,5-8, 11-15, 17-27), published-only abstracts (1-6, 9, 11-13), in progress articles (1-5, 7-8) • The AMA Physician’s Recognition Award Category 1 Credit = 147.25 points • The European Society of Medical Oncology Medical Oncologist’s Recertification Approval Category 1 Credit= 16 points • The European Continuous Medical Education Credit= 15 points • The Royal Col ege of Surgeons (UK) Category 1 Credit = 8 points • The Royal Col ege of Radiologists (UK) Category 1 Credit = 7 points • The Swiss Society of Medical Oncologists Category A Credit = 2 points • The Romanian National Medical Council (CMR) EMC Credit = 8 points TRAINING • Emotional Inteligence Program, TMI Romania, March 29th, 2008 • French: fluent • English: advanced upperway stage III, level IX, Wal Street Institute, Paris, France • Romanian: native language • Nationality: Romanian (EU member since January 2007) • Marital status: married, one child • EU driving license • No penal records, ability and wil ingness to travel • Web page: http://www.ad-astra.ro/whoswho/view_profile.php?user_id=1214&lang=en
BIBLIOGRAPHIC REFERENCES
Peer-reviewed journal articles = 26
Peer-reviewed journal articles (on behalf of cooperative groups) = 5
Peer-reviewed journal articles (with no impact factor) = 4
Oral presentations = 10
Poster presentations = 30
Published-only abstracts = 20
Original books (chapters) = 4
Under review articles = 5
In progress abstracts = 3
Peer-Reviewed Journal Articles (2009 ISI Journal Impact Factor=122.915)
Oudard S, Rixe O, Beuselinck B, Linassier C, Banu E, Machiels JP, Baudard M,
Ringeisen F, Velu T, Lefrere-Belda MA, Limacher JM, Fridman WH, Azizi M, Acres B, Tartour E. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cel carcinoma: clinical and immunological findings. Cancer Immunol Immunother 2011 Feb;60(2):261-271. [Epub ahead of print] 2010 Nov 11. 2. Fournier LS, Oudard S, Thiam R, Trinquart L, Banu E, Medioni J, Balvay D, Chatel ier
G, Frija G, Cuenod CA. Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology 2010 Aug;256(2):511-518. Epub 2010 Jun 15. 3. Oudard S, Banu E, Medioni J, Scotte F, Banu A, Levy E, Wasserman J, Kacso G,
Andrieu JM. What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel? BJU Int 2009 Jun;103(12):1641-1646. Epub 2009 Feb 6. 4. Fitzpatrick JM, Banu E, Oudard S. Prostate-specific antigen kinetics in localized and
advanced prostate cancer. BJU Int 2009 Mar;103(5):578-587. Epub 2009 Feb 6. Review. 5. Medioni J, Banu E, Hel ey D, Scotte F, Fournier L, Mejean A, Chedid A, Azizi M,
Andrieu JM, Oudard S. Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series. Eur Urol 2009 Jul;56(1):207-211, quiz 211. Epub 2009 Jan 13. 6. Berhoune M, Banu E, Scotte F, Prognon P, Oudard S, Bonan B. Therapeutic strategy for
treatment of metastatic non-smal cel lung cancer. Ann Pharmacother 2008 Nov;42(11):1640-1652. Oct 28. Epub 2008 Oct 28. 7. Riquet M, Cazes A, Pfeuty K, Ngabou UD, Foucault C, Dujon A, Banu E. Multiple lung
cancers prognosis: what about histology? Ann Thorac Surg 2008 Sep;86(3):921-926. 8. Hel ey D, Banu E, Bouziane A, Banu A, Scotte F, Fischer AM, Oudard S. Platelet
microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. Eur Urol 2009 Sep;56(3);479-484, Epub 2008 Jun 20. 9. Riquet M, Bagan P, Banu E. Reply. Ann Thorac Surg 2008;86(1):354.
Assouad J, Banu E, Brian E, Pham D.N, Dujon A, Foucault C, Riquet M. Strategies and
outcomes in pulmonary and extrapulmonary metastases from renal cel cancer. Eur J Cardiothorac Surg 2008 May;33(5):794-798. Epub 2008 Mar 4. 11. Scotté F, Banu E, Medioni J, Levy E, Ebenezer C, Marsan S, Banu A, Tourani JM,
Andrieu JM, Oudard S. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer 2008 Apr;112(7):1625-1631. Epub 2008 Feb 19. 12. Medioni J, Dionysopoulos D, Banu E, Scotte F, Oudard S. Chemotherapy for prostate
cancer. Presse Med 2008 May; 37(5 Pt 2):814-820. Epub 2007 Dec 21. Riquet M, Bagan P, Le Pimpec Barthes F, Banu E, Scotte F, Foucault C, Dujon A, Danel
C. Completely resected non-smal cell lung cancer: reconsidering prognostic value and significance of N2 metastases. Ann Thorac Surg 2007 Dec;84(6):1818-1824. 14. Banu E, Banu A, Fodor A, Landi B, Rougier P, Chatellier G, Andrieu JM, Oudard S.
Cumulative meta-analysis of randomized trials comparing gemcitabine-based chemotherapy versus gemcitabine alone in patients with advanced or/and metastatic pancreatic cancer. Drugs Aging 2007;24(10):865-879. 15. Oudard S, Banu E, Scotte F, Banu A, Medioni J, Beuzeboc P, Joly F, Ferrero J,
Goldwasser F, Andrieu JM. Prostate-specific antigen doubling time before onset of chemotherapy as survival predictor for hormone-refractory prostate cancer patients. Ann Oncol 2007 Nov;18(11):1828-1833. Epub 2007 Sep 9. 16. Banu E, Banu A, Medioni J , Levy E, Thiounn N, Mejean A, Andrieu JM, Oudard S.
Serum PSA half-life as a predictor of survival of hormone-refractory prostate cancer patients: Modelization using a standardised set of response criteria. Prostate 2007 Oct;67(14):1543-1549. 17. Medioni J, Cojocarasu O, Banu E, Cassar-Queudevil e A, Halimi P, Oudard S.
Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient. Targeted Oncology 2007 Jul;2(3):193-195. 18. Oudard S, Banu E, Scotte F, Beuzeboc P, Guyader C, Medioni J. New targeted therapies
in hormone-refractory prostate cancer. Bull Cancer 2007 Jul;94(7), suppl FMC:F62-68. 19. Oudard S, Banu E, Vieil efond A, Fournier L, Priou F, Medioni J, Banu A, Duclos B,
Rol and F, Arakaelyan N, Culine S. Prospective multicenter phase II study of Gemcitabine plus platinum salt for metastatic col ecting duct carcinoma patients. Results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study. J Urol 2007 May;177:1698-1702. 20. S. Oudard, J. Medioni, A. Chedid, E. Banu, D. Dionysopoulos, J. Balcaceres, F. Scotté.
Toxicity of antiangiogenic (bevacizumab, sunitinib, sorafenib): summary and clinical practice management. La Lettre du Cancérologue 2007 May;XVI(5):191-194. 21. Oudard S, Medioni J, Scotte F, Banu E. Prostate cancer: update. Bull Cancer 2005
Scotte F, Tourani JM, Banu E, Peyromaure M, Levy E, Marsan S, Magherini E, Fabre-
Guil evin E, Andrieu JM, Oudard S. A multicenter study to evaluate the use of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 2005 Jul;23(19):4424-4429. 23. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier
C, Scotte F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005 May;23(15):3343-3351. Epub 2005 Feb 28. 24. Oudard S, Carpentier A, Banu E, Fauchon F, Celerier D, Poupon MF, Dutril aux B,
Andrieu JM, Delattre JY. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J Neurooncol 2003 May;63(1):81-86. 25. Ciuleanu TE, Curca R, Iancu D, Todor N, Cebotaru C, Radulescu I, Banu E, Ghilezan N.
First-line chemotherapy with topotecan and etoposide in advanced smal cel lung cancer. A phase II study. J Buon 2002 Jan-Mar;7(1):43-46. 26. Zdrenghea D, Banu E, Bogdan E, Beudean M. The effect of low-dose amiodarone in
prevention of paroxysmal atrial fibril ation. Rom J Intern Med 1996 Jul-Dec;34(3-4):199-204.
Peer-Reviewed Journal Articles on behalf of cooperative groups
Launay-Vacher V, Gligorov J, Le Tourneau C, Janus N, Spano JP, Ray-Coquard I, Oudard S, Pourrat X, Morere JF, Deray G, Beuzeboc P; Renal Insufficiency and Anticancer Medications (IRMA) Study Group. Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat. 2010 Dec;124(3):745-753. Epub 2008 Aug 15. 2. Launay-Vacher V, Ayllon J, Janus N, Spano JP, Ray-Coquard I, Gligorov J, Pourrat X, Morere JF, Beuzeboc P, Deray G, Oudard S; Renal Insufficiency and Anticancer Medications (IRMA) Study Group. Drug management of prostate cancer: prevalence and consequences of renal insufficiency. Clin Genitourin Cancer. 2009 Oct;7(3):E83-89. 3. Launay-Vacher V, Spano JP, Janus N, Gligorov J, Ray-Coquard I, Oudard S, Pourrat X, Morere JF, Beuzeboc P, Deray G; Renal Insufficiency and Anticancer Medications (IRMA) Study Group. Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol. 2009 May;70(2):124-133. Epub 2008 Nov. 4. Launay-Vacher V, Etessami R, Janus N, Spano JP, Ray-Coquard I, Oudard S, Gligorov J, Pourrat X, Beuzeboc P, Deray G, Morere JF, Renal Insufficiency Anticancer Medications (IRMA) Study Group. Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung 2009 Jan-Feb;187(1):69-74. Epub 2008 Oct 22. 5. Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, Morere JF, Beuzeboc P, Deray G. On behalf of the Renal Insufficiency and Cancer Medications (IRMA)
Study Group. Prevalence of renal insufficiency in cancer patients and implications for anticancer
drug management: The renal insufficiency and anticancer medications (IRMA) study. Cancer
2007;110(6):1376-1384. Epub 2007 July 17.

Peer-Reviewed Journal Articles with No Impact Factor
Mihailov A, Ciuleanu TE, Todor N, Curca R, Iancu D, Taju N, Cebotaru C, Radulescu I, Neacsu C, Eniu A, Cainap C, Banu E, Homokos H, Ghilezan N. A phase II trial of Vinorelbine
and Cisplatin (VP) in stage IIIB non-smal cel lung cancer (NSCLC). Radioterapie & Oncologie
Medicala 2001;VII(2):158-162.
2.
Cebotaru C, Ghilezan N, Todor N, Popa L, Iancu D, Cainap C, Banu E, Eniu A,
Mihailov A, Homokos H. Gemcitabine in combination with “de Gramont” protocol as first-line chemotherapy for unresectable or metastatic pancreatic carcinoma. A phase II study. Radioterapie & Oncologie Medicala 2001;VII(1):77-84. 3. Banu E, Ghilezan N, Todor N, Cebotaru C, Radulescu I, Eniu A, Neacsu C, Cainap C,
Mihailov A, Iancu D. Bi-Monthly Irinotecan with High Dose Infusional Folinic Acid and 5 Fluorouracil for Advanced Inoperable, Metastatic or Relapsed Colorectal Carcinoma Patients. Radioterapie & Oncologie Medicala 2001;VII(1):85-91. 4. Banu E. Clinical Trials in Head and Neck Cancers. Radioterapie & Oncologie Medicala
Oral Presentations
Banu E, Oudard S, Levy E, Fabre-Guil evin E, Banu A, Ayl on J, Scotte F, Fodor A,
Andrieu JM. CA 125 dynamics during lifetime as prognostic factor for ovarian cancer (OC) patients. ESMO Scientific and Educational Conference, June 2-5, Budapest. Educational and Abstract Book 2005;16, suppl 2, i 296:94O. 2. Scotte F, Banu E, Oudard S, Banu A, Medioni J, Fabre-Guil evin E, Mejean A, Fontaine
E, Thiounn N, Andrieu JM. Prostate-specific antigen doubling-time (PSA DT) before onset of chemotherapy as survival predictor for hormone refractory prostate cancer (HRPC) patients. J Clin Oncol (suppl) 2005;23(16S):390s:4551. 3. Culine S, Oudard S, Duclos B, Banu E, Priou F, Rousseau F, Langlois D, Banu A,
Rol and F. A phase II prospective study of gemcitabine and platinum-based combination as first-line chemotherapy for metastatic Bellini duct carcinoma patients. Results of GETUG study. J Clin Oncol (suppl) 2005;23(16S):390s:4543. 4. Banu E: Prostate-specific antigen value in hormone-refractory prostate cancer treated
with chemotherapy. New horizons. 1st Journey of Prostate Cancer. Georges Pompidou European Hospital Symposium. 17 June 2004, Paris. 5. Banu E: Isolate biochemical relapse in prostate cancer patients treated with radical
prostatectomy or external radiotherapy as primary treatment: recommendations. The 4th West Urological Group Meeting. Ipsen Beaufour Symposium. June 16. Ile de Bréhat, 2004. 6. Scotte F, Tourani JM, Banu E, Peyromaure M, Jenabian A, Levy E, Coquelin K,
Magherini E, Marsan S, Oudard S. Assessment of frozen glove use in the prevention of docetaxel induced onycholysis and cutaneous reaction. Results of a multicenter case-control study. J Clin Oncol (suppl) 2004;22(14S);726:8003. 7. Le Frère-Belda MA, Banu E, Badoual C, Oudard S. Etude de l’expression du récepteur
du facteur de croissance épithélial R-EGF dans le cancer de la prostate et corrélations cliniques. Carrefour Pathologie 2003. Ann Pathol (suppl) 2003;23:IS114. 8. Oudard S, Banu E, Vannetzel JM, Beuzeboc P, Dourthe LM, Voog E, Hardy AC,
Kamioneur D, Coscas Y, Chauvet B. Results of a phase II trial of docetaxel (D), Estramustine (E) and prednisone (P)-two schedules, versus mitoxantrone (M) and prednisone in patients (pts) with hormone refractory prostate cancer (HRPC). Abstract Book of the 27th ESMO Congress, Nice, October 18-22. Ann Oncol 2002;13(suppl 5);90:325O. 9. Ciuleanu TE, Banu E, Todor N, Radulescu I, Cebotaru C, Popa L, Iancu D, Cainap C,
Eniu A, Mihailov A, Homokos H, Ghilezan N. Bi-weekly Gemcitabine + high dose infusional folinic acid and 5-Fluorouracil combination chemotherapy as first line chemotherapy for unresectable or metastatic pancreatic carcinoma patients. A phase II study. The 3th Eli Lilly Young Investigators Meeting, June 29-30, Indianapolis 2001. 10. Banu E. The genetic conditioner of the glaucoma and cataract (graduate presentation).
Genetic and Biology Division. University of Medicine. September 15. Cluj, Romania, 1992. Poster Presentations
E. Banu, D. Pelau, A. Porutiu, C. Floares, R. Buiga, M. Gal, A. Irimie. Stratify, adjust or
interact in time-to-event analysis in ovarian cancer patients? Lesson to be learned. 13th Biennial Meeting of the International Gynecologic Cancer Society, Abstract Book, 23-26 October, 2010, Prague. Gynecologic Oncology: 00588. 2. E. Banu, C. Floares, B. Gherghel, D. Pelau, V. Manolescu, V. Gal, V. Muresan, A.
Porutiu, I. Maguran. A predictive model to estimate the true risk of severe neutropenia in cancer patients treated with chemotherapy. 35th ESMO Congress. Abstract Book, 8-12 October, 2010, Milan. Annals of Oncology:4688;1259P. 3. Banu E. The relative dose-intensity and new targeted therapies in breast cancer patients.
Facts and hypotheses. 7th European Breast Cancer Conference. Abstract Book, 24-27 March 2010, Barcelona. EJC 2010;8(3), suppl, 87: abstr 98. 4. Muresan V, Muresan A, Pelau D, Banu E. Multidisciplinary approach for a local y
advanced colon cancer with multiple local recurrences and brain metastasis. ECCLU- Educational Cancer Convention, Lugano, 3 July 2009, Ann Oncol 2009;20, suppl 5, v17:40. 5. E. Banu, D. Pelau, A. Porutiu, C. Burz, T. Banciu, F. Zsuzsa, A. Ciopec. Monotherapy
with Capecitabine (Xeloda) for metastatic colo-rectal patients. Green Event, Roche Symposium, 27-28 November 2009, Sibiu, Romania: abstr 41. 6. Banu E. Delayed chemotherapy and/or dose reduction. A model to accurately predict the
dose-intensity. The Breast, Volume 18, Supplement 1, March 2009, Page S37. 11th International Conference on Primary Therapy of Early Breast Cancer, 12 March 2009, St. Gal en:0076. 7. Banu E. How to prescribe standard chemotherapy or targeted-therapy using a ful y
featured relational database. 21-24 October 2008. The 20th EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics. Geneva. Eur J Cancer 2008;6(12):61;194. 8. Banu E, Oudard S, Banu A. Proposal for a new approach in time-to-event univariate
analyses. 17-21 August 2008, 29th Annual Conference of the International Society for Clinical Biostatistics, Copenhagen:220. 9. E. Banu, A. Banu. Chemotherapy combined with melatonin treatment in a patient with
metastatic non-smal cel lung cancer. 9-12 July 2008, International Lung Cancer Conference, Liverpool; Journal of Thoracic Oncology (Supp): abstr 8. 10. S. Oudard, E. Banu, I. Latorzeff, A. Caty, L. Miglianico, F. Rolland, F. Priou, M.
Mourey, P. Beuzeboc, S. Culine. Non-metastatic high-risk prostate cancer patients with biochemical relapse only after local treatment. A prospective randomized phase III study comparing hormonal therapy +/-docetaxel. Proceedings of Genitourinary Cancers Symposium, 14-16 February 2008, San Francisco;212. 11. Medioni J, Cassar-Queudevil e A, Fournier L, Banu E, Cuenod CA, Oudard S. Response
of renal cel carcinoma pancreatic metastases to sunitinib treatment: A retrospective analysis. A17. Molecular Targets and Cancer Therapeutics, San Francisco, October 22-26, 2007 (AACR-NCI-EORTC Conference). 12. Scotte F, Dionysopoulos D, Piquet V, Guittard F, Medioni J, Banu E, Oudard S.
Assessment of distant surveil ance in a patient receiving oral antiangiogenic treatment at home. P-214. Abstracts of the 20th International MASCC/ISOO Symposium, St. Gal en, June 27-30. Support Care Cancer 2007;15:784. 13. Hel ey D, Banu E, Bouziane A, Banu A, Oudard S, Fischer A.M. Platelet microparticles
are a predictive factor of overal survival in patients with prostate cancer. PS 525. The XXIst
Congress of the International Society on Thrombosis and Haemostasis, Geneva, July 6-12, J
Thromb Haemost 2007;5(suppl 2):2411.
14.
Scotte F, Banu E, Medioni J, Levy E, Ebenezer C, Marsan S, Banu A, Andrieu JM,
Oudard S. Frozen sock use in the prevention of docetaxel-induced nails and skin toxicities.
Results of a case-control study. J Clin Oncol (suppl) 2007;25(18S):9059.
15.
Oudard S, Banu E, Medioni J, Dionysopoulos D, Cojocarasu O, Banu A. What is the real
impact of the bone pain on survival of hormone-refractory prostate cancer (HRPC) patients treated with docetaxel? J Clin Oncol (suppl) 2007;25(18S):5149. 16. Hel ey D, Banu E, Bouziane A, Banu A, Oudard S, Fischer A. Les taux de
microparticules plaquettaires (Mps) sont un facteur prédictif de la survie chez les patients présentant un cancer de la prostate hormono-résistant et traités par chimiothérapie. The congress of the French Society of Hematology, Paris, March 2007. Hématologie (suppl) 2007;12(1): 17. Banu A, Hel ey D, Banu E, Fischer AM, Scotte F, Bouziane A, Oudard S. Platelet
microparticles (PMP): A predictive factor of survival in hormone-refractory prostate cancer (HRPC) patients treated by chemotherapy. J Clin Oncol (suppl) 2006;24(18S);251s:4639. 18. Banu E, Rixe O, Linassier C, Machiels JP, Baudard M, Ringeisen F, Velu T, Lefre-Belda
MA, Limacher JM, Oudard S. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal cel carcinoma (RCC) in metastatic renal cell carcinoma. J Clin Oncol (suppl) 2006;24(18S);120s:2581. 19. Banu E, Fischer AM, Oudard S, Bouziane A, Banu A, Helley D. Platelet microparticles
(PMP): A predictive factor of survival in hormone-refractory prostate cancer (HRPC) patients treated by chemotherapy. Proceedings of Prostate Cancer Symposium, February 26, San Francisco, 2006;175:358. 20. Banu E, Oudard S, Banu A, Fodor A, Landi B, Lecomte T, Laurent-Puig P, Cugnenc
PH, Andrieu JM. Cumulative meta-analysis of randomized trials comparing gemcitabine-based chemotherapy versus gemcitabine alone in patients with advanced or metastatic pancreatic cancer (PC). J Clin Oncol (suppl) 2005;23(16S);333s:4101. 21. Oudard S, Banu E, Banu A, Scotte F, Levy E, Medioni J, Fabre-Guil evin E, Ayl on J,
Arakelyan N, Andrieu JM. Docetaxel versus mitoxantrone as first-line chemotherapy for hormone-refractory prostate cancer (HRPC) patients. A meta-analysis of 3-year overall survival results. J Clin Oncol (suppl) 2005;23(16S);411s:4634. 22. Beuzeboc P, Banu E, Goubely-Brewer Y, Banu A, Zerbib M, Flam T, Peyromaure M,
Scotte F, Andrieu JM. Corrected area under prostate-specific antigen (PSA) curve and PSA half-time dynamics during chemotherapy. A new prognostic classification for hormone-refractory prostate cancer (HRPC) patients. J Clin Oncol (suppl) 2005;23(16S);413s:4641. 23. Oudard S, Banu E, Zerbib M, Flam T, Banu A, Peyromaure M, Scotte F, Andrieu JM.
Corrected area under prostate-specific antigen (PSA) curve and PSA half-time dynamics during chemotherapy. A new prognostic classification for hormone-refractory prostate cancer (HRPC) patients. Proceedings of Prostate Cancer Symposium, February 19, Orlando, 2005;170:272. 24. Oudard S, Banu E, Banu A, Medioni J, Mejean A, Fontaine E, Thiounn N, Scotte F,
Andrieu JM. Prostate-specific antigen doubling-time (PSA DT) before onset of chemotherapy as survival predictor for hormone refractory prostate cancer (HRPC) patients. Proceedings of Prostate Cancer Symposium, February 19, Orlando, 2005;175:281. 25. Banu E, Oudard S, Banu A, Levy E, Thiounn N, Mejean A, Arakelyan N, Scotte F,
Andrieu JM. Combination of prostate-specific antigen (PSA) exposure and Gleason score as prognostic factors for prostate cancer (PC) patients. Proceedings of Prostate Cancer Symposium, 17 February, Orlando, 2005;70:73. 26. Banu E, Levee M, Scotte F, Banu A, Oudard S, Ayl on J, Le Maignan C, Bonan B, Le
Louet AL, Andrieu JM. Corrected area under serum hemoglobin curve (Hb c-AUC) as a predictor of maximal hemoglobin response after erythropoietin (rHuEpo) treatment in chemotherapy induced anemia patients. J Clin Oncol (suppl) 2004;22(14S);852:9586. 27. Oudard S, Banu E, Thiounn N, Zerbib M, Flam T, Debré D, Banu A, Scotte F, Andrieu
JM. Corrected area under serum PSA curve as a predictor of survival after chemotherapy for hormone-refractory prostate cancer (HRPC) patients. J Clin Oncol (suppl) 2004;22(14S);850:9579. 28. Oudard S, Banu E, Vannetzel JM, Beuzeboc P, Dourthe LM, Voog E, Hardy AC,
Kamioneur D, Coscas Y, Chauvet B. Results of a phase II trial of docetaxel (D), Estramustine (E) and prednisone (P)-two schedules, versus mitoxantrone (M) and prednisone in patients (pts) with hormone refractory prostate cancer (HRPC). Congress of the European Association of Urology, March 13-15, Madrid. Eur Urol (suppl 1) 2003;2;189:746. 29. Oudard S, Banu E, Banu A, Scotte F, Levy E, Le Maignan C, Andrieu JM. Prostate-
specific antigen half-time (PSAHT) as a predictor of survival for hormone-refractory prostate cancer (HRPC): A standardized set of response criteria. Proc Am Soc Clin Oncol 2003;22;416:1673. 30. Banu E, Ghilezan N, Todor N, Radulescu I, Cebotaru CL, Florea R, Ciuleanu TE. FU
FOL - pal iative chemotherapy in colorectal carcinomas. Results of a series of patients treated at the Cancer Institute in Cluj. The 8th European Interuniversity Symposium, Hel as, 1998. Published-only Abstracts (Proceedings Book)
J. Ayl on, E. Banu, F. Leviel, P. Houillier, J. Medioni, E. Barrascout, S. Oudard, G.
Maruani. Bone markers in prostate cancer (PC) patients: Biologic criteria to identify patients at risk of developing distant metastases. J Clin Oncol (suppl) 2009;27(15S):e16069. 2. F. Scotte, E. Banu, J. Medioni, M Boudraoui, J.M. Tourani, A. Banu, S. Oudard. Impact
of nail toxicity on survival of patients with hormone-refractory prostate cancer (HRPC) treated with docetaxel. J Clin Oncol (suppl) 2009;27(15S):e16122. 3. Banu A, Banu E, Dionysopoulos D, Medioni J, Scotte F, Levy E, Oudard S.
Chromogranine A and neuron-specific enolase as the main predictors of survival for hormone-refractory prostate cancer (HRPC) patients. J Clin Oncol (suppl) 2007;25(18S):15594. 4. Banu E, Scotte F, Banu A, Medioni J, Brizard M, Levy E, Oudard S. Is the natural
history of prostate cancer different according to serum neuroendocrine profile? J Clin Oncol (suppl) 2007;25(18S):15536. 5. Berhoune M, Fabre-Guillevin E, Banu E, Scotte F, Bonan B, Medioni J, Cojocarasu O,
Ridel er K, Ayl on J, Levy E. What is the place of clinical variables in advanced non-smal cel lung cancer (NSCLC) patients treated with chemotherapy? J Clin Oncol (suppl) 2007;25(18S):18197. 6. Beuzeboc P, Banu E, Voog E, Bousquet G, Priou F, Deplanque G, Bozec L, Machiels
JP, Vannetzel M, Oudard S. Trastuzumab (T) combined with standard chemotherapy in HER+ metastatic bladder cancer (BC) patients. Interim safety results of a prospective randomized phase II study. J Clin Oncol (suppl) 2007;25(18S):15565. 7. Fournier L, Thiam R, Cuenod C, Medioni J, Trinquart L, Balvay D, Banu E, Balcaceres
J, Frija G, Oudard S. Dynamic contrast-enhanced CT (DCE-CT) as an early biomarker of response in metastatic Renal Cel Carcinoma (mRCC) under anti-angiogenic treatment. J Clin Oncol (suppl) 2007;25(18S):14003. 8. Medioni J, Arakelyan N, Fournier L, Hel ey D, Thiam R, Ebenezer C, Banu E, Cuenod C,
Oudard S. Relation between Lactate Deshydrogenase (LDH) during firsts cycles in patients with kidney cancer (KC) treated with sunitinib (SU). J Clin Oncol (suppl) 2007;25(18S):14079. 9. Ayl on J, Oudard S, Banu E, Janneau JL, Helley D, Richon S, Banu A, Levy E, Medioni
J, Bel et D. Early placenta insulin-like peptide (pro-EPIL): a novel biomarker in advanced and
metastatic non-smal cel lung cancer (NSCLC) patients treated by chemotherapy. J Clin Oncol
(suppl) 2006;24(18S);706s:20069.
10.
Linassier C, Oudard S, Rixe O, Machiels JP, Rossi JF, Ringeisen F, Velu T, Banu E,
Acres B, Squiban P. Phase II study of the cancer vaccine TG4010 in metastatic renal cel carcinoma. J Clin Oncol (suppl) 2005;22(16S);416s:4653. 11. Banu A, Oudard S, Banu E, Kamioneur D, Housset M, Thiounn N, Jenabian A, Mejean
A, Andrieu JM. Combination of prostate-specific antigen (PSA) exposure and Gleason score as prognostic factors for prostate cancer (PC) patients. J Clin Oncol (suppl) 2005;23(16S);430s:4709. 12. Vieil efond A, Beuzeboc P, Mignot L, Banu E, Priou F, Malaurie E, Dalivoust P,
Murracciole X, Sibony M, Oudard S. HER2 status in orothelial bladder cancer (UC): screening of patients eligible for a phase II randomized study of gemcitabine plus platinum salt with or without trastuzumab. J Clin Oncol (suppl) 2005;23(16S);427s:4700. 13. Ayl on J, Plazanet V, Fabre-Guillevin E, Banu E, Bonan B, Oudard S, Le Pimpec Barthes
F, Theou N, Sors H, Andrieu JM. Optimum timing of Gefitinib therapy in metastatic non-smal cel lung cancer (NSCLC) patients. J Clin Oncol (suppl) 2005;23(16S);700s:7323. 14. Ciuleanu TE, Curca R, Banu E, Iancu D, Todor N, Cebotaru C, Radulescu IL, Ghilezan
N. Topotecan and etoposide first line chemotherapy of advanced small cell lung cancer. A phase II study. Eighteenth UICC International Cancer Conference, June 30-July 5. International Journal of Cancer 2002;100, Issue S13;431-463:P964. 15. Ciuleanu TE, Cebotaru C, Banu E, Radulescu I, Homokos H, Mihailov A, Todor N,
Ghilezan N. A randomised phase II trial of Taxol + Cisplatin (TP) versus Etoposide + Cisplatin (EP) in advanced non-small cel lung cancer. Radioterapie & Oncologie Medicala 2000;6(suppl 2);47S:111. 16. Ciuleanu TE, Banu E, Todor N, Radulescu I, Cebotaru CL, Popa L, Iancu D, Cainap C,
Eniu A, Mihailov A, Homokos H, Ghilezan N. Bi-weekly Gemcitabine + high dose infusional Folinic acid and 5-Fluorouracil combination chemotherapy as first line chemotherapy for unresectable/metastatic pancreatic carcinoma patients. A phase II study. Radioterapie & Oncologie Medicala 2000;6(suppl 2);24S:52. 17. Ciuleanu TE, Todor N, Banu E, Cebotaru CL, Radulescu I, Eniu A, Neacsu C, Cainap C,
Mihailov A, Iancu D, Homokos H, Ghilezan N. Bi-weekly Irinotecan + high dose infusional Folinic acid and 5-FU combination chemotherapy as first line chemotherapy for advanced inoperable, metastatic or relapsed colorectal carcinoma patients. A phase II study. Radioterapie & Oncologie Medicala 2000;6(suppl 2) ;23 S:50. 18. Ciuleanu TE, Radulescu I, Banu E, Cebotaru CL, Todor N, Eniu A, Florea R, Ghilezan
N. Les carcinomes colorectaux; même questions, nouvelle réponses: CPT 11. National Meeting in Medical Oncology, Poiana Brasov, Roumanie 1997. 19. Banu E, Ghilezan N, Todor N, Radulescu I, Cebotaru CL, Florea R, Ciuleanu TE. FU
FOL - pal iative chemotherapy in colorectal carcinomas. Results of a series of patients treated at the Cancer Institute in Cluj. 7th European Interuniversity Symposium at Aristoteles Institute, Thessaloniki, Greece 1997(17):50. 20. Ciuleanu E, Popita V, Banu E, Ghilezan N, Todor N, Ciuleanu TE. Clinical versus
computer tomographic assessment for nasopharyngeal carcinomas. Radioterapie & Oncologie
Medicala 1997;6.

In progress abstracts
S. Oudard, I. Latorzeff, P. Beuzeboc, E. Banu, A. Caty, E. Sevin, R. Delva, F. Rol and,
F. Priou, R. T. Elaidi, S. Culine. Risk-reduction with addition of docetaxel (D) to hormonal therapy (HT) vs HT alone in non-metastatic high-risk prostate cancer (PC) patients (pts): final results on PSA progression-free survival. J Clin Oncol (suppl) 2011;29(18S):84423. 2. G. Maruani, R. T. Elaidi, J. Gachet, E. Kempf, M. Brizard, E. Banu, F. Leviel, C.
Gauci, S. Oudard. Baseline procol agen type I n-terminal propeptide (P1NP) is predictive of overal survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (Pts) treated with sunitinib (S) after docetaxel failure: A prospective study. J Clin Oncol (suppl) 2011;29(18S):83881. 3. D. Helley, R. T. Elaidi, J. Gachet, E. Kempf, M. Brizard, E. Levionnois, E. Banu, S.
Oudard. Assessment of angiogenic factors and hematopoïetic stem cells and their relevance as prognostic factors for overal survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A prospective study. J Clin Oncol (suppl) 2011;29(18S):84672. Original Books (chapters)
Riquet M, Banu E, Foucault C. Unknown primary malignancy metastatic to thoracic
lymph nodes. General Thoracic Surgery, 7th edition, 2009. Edited by Thomas W. Shields, Joseph LoCicero III, Carolyn E. Reed, Richard H. Feins. Wolters Kluwer. Chapter 112:1435-1439. 2. Banu E, Oudard S. Le cancer de la prostate. Intérêt de la mesure de la demi-vie du PSA
et l'aire sous la courbe du PSA. Nouveaux standards d'évaluation thérapeuthiques? Edition Ellipses 2005;Chapter 10:125-131. 3. Oudard S, Banu E, Banu A, Andrieu JM. Le livre de l'année. Cancérologie. Cancers
urologiques. Octopus Multimedia 2004:43-56. 4. Oudard S, Banu E, Banu A, Andrieu JM. Le livre de l'année. Cancérologie. Cancers
urologiques. Editure Ellipses 2003:45-58. Accepted for Publication Peer-Reviewed Articles
Under Review Articles
Banu E, Banu A. Survival analysis in clinical trials in oncology. A critical review.
American Journal of Clinical Oncology. 2. Banu E, Buiga R. CA-125 dynamics during lifetime as prognostic factor for ovarian
cancer patients. Gynecologic Oncology. 3 Banu E, Porutiu A, Buiga R, Oudard S. Complete response of brain metastases with
concomitant radiotherapy and temozolomide in a melanoma patient. Lesson to learn from molecular markers. American Journal of Clinical Oncology.

Source: http://www.doctorbun.ro/fisiere/cv/www_doctorbun_ro_1073_dr_eugeniu_banu.pdf